Management Team

Argos' senior management has extensive pharmaceutical and biotechnology industry experience including the clinical development, regulatory approval and commercial introduction of oncology products, as well as the manufacturing scale-up and launch of "blockbuster" products.

Clint G. Dederick, Jr., M.B.A. Chairman, CEO and President
Jeffrey D. Abbey, M.B.A., J.D. Vice President, Business Development
Lothar H. Finke, M.D. Vice President, Clinical Development
Frederick M. Miesowicz, Ph.D. Vice President, Manufacturing and Process Development
Charles A. Nicolette, Ph.D. Vice President, Research and Development
Timothy W. Trost, C.P.A. Vice President, Chief Financial Officer
Douglas Winship Vice President, Quality Assurance and Regulatory Affairs


Clint G. Dederick, Jr.
Chairman of the Board, CEO and President
Clint Dederick brings over 30 years of experience in the pharmaceutical and biotechnology industries to Argos Therapeutics. He has served as chairman of the board since the company’s inception. Dederick was group director, venture projects, of Senmed Medical Ventures for 15 years prior to becoming CEO and president of Argos Therapeutics in 2002. He also served on the boards of several companies during his tenure with Senmed. Prior to joining Senmed, Dederick worked with Praxis Biologics, Inc., Seragen, Inc., and Collaborative Research, Inc. He also worked with Eli Lilly & Co., where he was engaged with a variety of domestic and international assignments over a period of ten years. Dederick’s academic background includes an undergraduate degree from the University of Delaware in biology and chemistry, and a M.B.A. from the University of Virginia Darden School.
return to top

Jeffrey D. Abbey, M.B.A., J.D.
Vice President, Business Development
Jeffrey Abbey joined Argos Therapeutics in September 2002. Before joining Argos, Abbey was Vice President of Business Development and Finance for Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a partner in Ehrenreich Eilenberg and Krause, a boutique corporate law firm, where he acted as business counsel for a number of life sciences and other emerging technology companies. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. He holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.
return to top

Lothar H. Finke, M.D.
Vice President of Clinical Development
Lothar Finke, M.D., joined Argos Therapeutics to lead clinical development efforts for a broad range of therapies. Dr. Finke has nine years of biotech oncology development experience in the pharmaceutical industry - both in Europe and the United States. Additionally, he has six years of clinical experience in surgical oncology and 10 years of experience in molecular and cell-biology.

Prior to joining Argos, Dr. Finke worked for a number of companies, including EMD Pharmaceuticals, Lexigen Pharmaceuticals, and Merck KGaA. Academically, Dr. Finke worked at the Max Delbrueck Center for Molecular Medicine, the Basel Institute for Immunology, Ruprecht Karls University of Heidelberg, and Philipps University, Marburg/Lahn, Germany. As part of his industry experience, he is trained and experienced in regulatory affairs, drug safety, clinical development relevant to Europe, the United States, Canada, and Japan.

Dr. Finke received both his medical degree and cellbiology doctorate from Philipps University of Marburg in Lahn, Germany.
return to top

Frederick M. Miesowicz, Ph.D.
Vice President, Manufacturing and Process Development
Frederick Miesowicz joined Argos Therapeutics in May 2003. Prior to this, Miesowicz was the Vice President of U.S. Operations for Gamida-Cell, a stem cell company. He was Senior Vice President and General Manager of Hybridon Specialty Products. He served as Senior Vice President of Scientific Affairs at Cellcor from 1992 to 1995 and as Vice President and General Manager of Cellcor, a subsidiary of Cytogen Inc., from 1995 to 1998, where he directed all operations related to Cellcor’s cellular immunotherapy programs. Miesowicz has an extensive background in cellular therapies and medical devices. Prior to joining Cellcor, he managed the U.S. and European SteriCell Division of Terumo Medical Corporation after it was acquired from DuPont, and was with E.I. DuPont de Nemours & Company for over 14 years managing both immunotherapy and immunodiagnostic R&D groups. He holds a BS degree in Chemistry from Siena College and received a Ph.D. in Chemistry from Harvard University.
return to top

Charles A. Nicolette, Ph.D.
Vice President, Research and Development
Charles Nicolette joined Argos Therapeutics in August 2003. Nicolette has extensive experience in the field of cancer vaccines and is the inventor on dozens of patent applications and issued patents relating to vaccine development for cancer and infectious diseases. He was formerly the Director of Antigen Discovery at Genzyme Molecular Oncology where he developed SPHERE technology, the subject of one of the largest biotechnology deals ever done in the field of tumor antigen discovery. He is an expert in cellular immunology and brings substantial immunological sophistication to Argos. Nicolette received his Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.
return to top

Timothy W. Trost, CPA
Vice President & Chief Financial Officer
Timothy Trost joined Argos Therapeutics in July 2002. Prior to joining Argos, Trost most recently served as senior vice president & chief financial officer of InteCardia, Inc., a venture-backed cardiology development firm sold to Syncor International (NASDAQ: SCOR) in August 2001. Prior to InteCardia, he served as senior vice president of corporate development and later as executive vice president and chief financial officer of Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency room physicians. Prior to that, Trost served as vice president of finance / controller of Morganite North America, Inc., the US holding company for The Morgan Crucible Company plc (London exchange). He began his professional career with a total of twelve years (in four offices) at the international accounting and consulting firm of Price Waterhouse. Trost holds a degree in accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
return to top

Douglas Winship
Vice President, Quality Assurance and Regulatory Affairs
As Vice President of Quality Assurance and Regulatory Affairs, Doug Winship is responsible for directing and managing the preparation of regulatory submissions for current and new products being developed by the company, as well as interfacing with regulatory agencies and corporate partners on quality, regulatory, technical and business issues. He is also responsible for assuring that manufacturing and development operations within the company comply with cGMP, cGLP and cGCP requirements as required by regulatory agencies worldwide. Prior to joining Argos, Winship previously was an executive officer at CEL-SCI Corp. and Curative Technologies, Inc., Earlier in his career, Winship worked at Seapharm, Inc., Oxford Research International Corp., Revlon Health Care Group and Schering Plough, Inc.

Additionally, Winship’s expertise includes regulatory affairs, quality assurance, clinical development and trial management, clinical protocol development for cancers and infectious disease, and strategic planning. Winship has been involved in over 35 INDs, 12 NDAs/PLAs and 6 ANDAs for drug and biological products in a number of therapeutic areas including cancer, wound healing, infectious diseases and cardiovascular diseases. In addition, Winship has established Regulatory Affairs and Quality Assurance departments at VC-backed companies, and managed the successful development of SOP and documentation systems. He has coordinated submissions to regulatory agencies and Ethics Committees in support of the conduct of trials in Canada, UK, Sweden, Belgium, Germany, Netherlands, Poland, Czech Republic, Hungary and Israel. He has also set up and administered trials in United States, Canada, Hungary, Poland, Czech Republic, Netherlands and Israel.

He received a B.S. in Chemistry from Upsala College in New Jersey.
return to top